Knight Therapeutics Inc. (TSX:GUD)

Market Cap	730.36M +17.4%
Revenue (ttm)	450.09M +21.2%
Net Income	-5.37M
EPS	-0.05
Shares Out	98.03M
PE Ratio	n/a
Forward PE	45.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,529
Average Volume	106,278
Open	7.44
Previous Close	7.44
Day's Range	7.41 - 7.50
52-Week Range	5.43 - 7.50
Beta	0.04
RSI	82.23
Earnings Date	Mar 19, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 830
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD